(UroToday.com) Following presentations from Dr. Sadeghi on the role of pembrolizumab and sEphB4-HAS in patients with previously treated metastatic urothelial carcinoma and from Dr. Pfister on the role of ddMVAC as neoadjuvant chemotherapy in those with muscle-invasive disease, Dr. Enrique Grande provided an invited discussion to contextualize these papers in the Proffered Paper session of the European Society for Medical Oncology (ESMO) Annual Congress focusing on non-prostate cancer genitourinary tumors.